Japanese Encephalitis Archives
Japanese Encephalitis
Genotype III-Based Japanese Encephalitis Vaccines Exhibit Diminished Neutralizing Response to Re-emerging Genotype V
Japanese encephalitis (JE) has been predominantly controlled through vaccination. However, the isolation of JE virus (JEV) genotype V (GV) in China in 2009, and the subsequent alarming increase in JE cases in the Republic of Korea since 2010, present a new challenge. Serum samples from individuals vaccinated...
Japanese Encephalitis
Genetic diversity and Wolbachia infection in the Japanese encephalitis virus vector Culex tritaeniorhynchus in the Republic of Korea
Culex tritaeniorhynchus Giles, 1901 is a mosquito species with a global distribution that includes Africa, Asia, Australia and Europe [1, 2] and is a primary vector of Japanese encephalitis virus (JEV). Enzootic transmission of JEV occurs through amplifying hosts, such as pigs and water birds....
Japanese Encephalitis
Japanese encephalitis virus-associated human microglia induce cell death of human microvascular endothelial cells in receptor-independent infection.
The neurotropic virus Japanese encephalitis virus invades the human central nervous system, inducing neuroinflammation and further disruption of the blood-brain barrier. JEV interacts with various cell types of the blood-brain barrier including the endothelial cells. The present work aims to investigate...
Japanese Encephalitis
Japanese Encephalitis in Asia: A Comprehensive Review.
Japanese encephalitis (JE) which is caused by Japanese encephalitis virus (JEV) is a significant public health concern in Asia. The JEV is mainly transmitted by Culex mosquitoes breeding in flooded rice fields. The disease can range from mild flu-like symptoms to severe encephalitis and long-term neurological...
Japanese Encephalitis
National burden of and optimal vaccine policy for Japanese encephalitis virus in Bangladesh: a seroprevalence and modelling study
Bangladesh first reported Japanese encephalitis virus (JEV) in 1977 and has seen regular cases since; however, no JEV vaccination programme currently exists. A barrier to the use of JEV vaccines has been a limited understanding of the underlying burden. We conducted a nationally representative serological...
